PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML

• N. Daver,
• M. Maris,
• R. Ramchandren,
• D. Bixby,
• K. Doucette,
• R. Mawad,
• D. Egan,
• D. Stevens,
• J. Zonder,
• N. Molloy,
• A. Scheuber,
• I. Bruns,
• I. Mantzaris,
• M. Konopleva,
• A. D. Goldberg

Affiliations

N. Daver

1 University of Texas MD Anderson Cancer Center, Houston

M. Maris

2 Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver

R. Ramchandren

3 University of Tennessee, Knoxville

D. Bixby

4 University of Michigan, Ann Arbor

K. Doucette

5 Georgetown University Hospital, Washington, DC

R. Mawad

6 Swedish Cancer Institute, Seattle

D. Egan

6 Swedish Cancer Institute, Seattle

D. Stevens

7 Norton Healthcare, Louisville

J. Zonder

8 Karmanos Cancer Institute/Wayne State University, Detroit

N. Molloy

9 Trillium Therapeutics, a Pfizer company’, Cambridge

A. Scheuber

9 Trillium Therapeutics, a Pfizer company’, Cambridge

I. Bruns

9 Trillium Therapeutics, a Pfizer company’, Cambridge

I. Mantzaris

10 Einstein College of Medicine

M. Konopleva

1 University of Texas MD Anderson Cancer Center, Houston

A. D. Goldberg

11 Memorial Sloan Kettering, New York, United States of America